At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 100 target
Drug / intervention
HB0025drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of HB0025 in Patients With Advanced Renal Cancer
In Brief
A Phase 2 clinical trial evaluating HB0025 for Renal Cancer. Targeting 100 participants across 1 site.
Detailed Summary
It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
Enrollment StartJan 2023
First PostedJan 2024
Primary CompletionJan 2025
Study CompletionDec 2025
TodayJul 2026
First PostedJan 24, 2024
Enrollment StartJan 30, 2023
Primary CompletionJan 30, 2025
Study CompletionDec 30, 2025
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.4 years ago
Interventions
HB0025drug
HB0025 IV every 2 weeks (q2w)